---
schema_version: "secwatch.filing_event.v1"
accession: "0001847367-25-000026"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:20:18.319313+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alumis Q1 net loss $99M, revenue $17.4M; merger with ACELYRIN on track for Q2 2025 close

## Summary
- Net loss of $99M in Q1 2025 vs $49.8M in Q1 2024; revenue of $17.4M from Kaken license fee.
- Cash and marketable securities $208.7M as of March 31, 2025; combined pro forma cash $737M with ACELYRIN.
- Merger with ACELYRIN approved by Alumis stockholders; exchange ratio 0.4814; expected close in Q2 2025.
- ESK-001 Phase 3 psoriasis topline data expected early Q1 2026; SLE Phase 2b data in 2026.
- R&D expenses $96.6M (up 130% YoY) driven by Phase 3 ONWARD program acceleration.

## SEC filing metadata
- accession: 0001847367-25-000026
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/0001847367-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847367-25-000026
- JSON: https://secwatch.observer/filing/0001847367-25-000026.json
- Plain text: https://secwatch.observer/filing/0001847367-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.